Nat Commun: Double blocking cd47 and HER2 can eliminate radiotherapy resistance in breast cancer cells.

Radiotherapy (RT) has relatively small systemic side effects compared to chemotherapy and is used in all subtypes of breast cancer (BC) treatment.
, however, due to potential tumor radiotherapy resistance, it can eventually lead to recurrence or metastasis of the patient's tumor.
, RT's treatment strategies combined with targeted immunotherapy (TI) are increasingly being used in the treatment of a variety of cancers.
although TI can enhance the effectiveness of radiation therapy for cancer, the relevant immunosuppressive factors induced by radiotherapy have yet to be identified.
CD47 and HER2 in a variety of cancers, the study found that CD47-mediated anti-devouration increased in radiotherapy-resistant breast cancer (BC) cells, while HER2 expression levels increased.
the co-expression of these two subject proteins is often detected in patients with relapsed BC with poor prognostication.
The expression of CD47 in HER2-expressed cells was prioritized, while blocking the expression of CD47 or HER2 reduced the levels of both proteins, along with a decrease in cell formation capacity and increased phagocytosing.
double blocking CD47 and HER2 have the same synergetic anti-cancer effect as radiotherapy, and the double knock-off of CD47 and HER2 by CRISPR technology can not only inhibit the formation of cell colonies, but also enhance the attack ability of macrophages on tumor cells.
further studies have shown that in breast tumors in esophageal mice, the double antibodies of these two subject proteins have a synergetic anti-cancer effect with RT.
the results of the comprehensive study of radiotherapy-resistant breast cancer cell model show that the aggressive effect of radiation-resistant breast cancer cells is caused by CD47-mediated anti-swallowing effect and HER2-mediated cell proliferation.
double blocking of CD47 and HER2 can counteract radiotherapy resistance in breast cancer cells.
.